Key Points
- Director Edward Md Kaye sold 13,430 shares on December 8 at an average price of $32.27 for a total of $433,386, reducing his stake by 21.47% to 49,124 shares (valued at about $1.59M).
- STOK opened at $34.15 with a 50‑day/200‑day moving average of $29.55/$20.39, a 52‑week range of $5.35–$38.69, a market cap of $1.95B and a P/E of 50.97.
- The company reported a quarterly loss of ($0.65) EPS“Buy” rating with an average target of $31.00.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $32.28, for a total value of $128,409.84. Following the transaction, the general counsel directly owned 11,831 shares of the company's stock, valued at $381,904.68. This trade represents a 25.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Jonathan Allan also recently made the following trade(s):
- On Friday, December 5th, Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.29, for a total value of $274,882.65.
- On Thursday, December 4th, Jonathan Allan sold 1,018 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total value of $31,425.66.
- On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.65, for a total value of $70,249.80.
- On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
- On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $250,700.00.
Stoke Therapeutics Trading Up 1.8%
NASDAQ STOK opened at $34.76 on Thursday. The firm has a market capitalization of $1.99 billion, a P/E ratio of 51.81 and a beta of 1.14. The firm's fifty day moving average price is $29.55 and its two-hundred day moving average price is $20.39. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.11). The firm had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on STOK shares. Needham & Company LLC boosted their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, October 10th. JPMorgan Chase & Co. lifted their target price on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a "neutral" rating in a research note on Monday, November 3rd. Weiss Ratings restated a "hold (c)" rating on shares of Stoke Therapeutics in a research note on Monday. BTIG Research reaffirmed a "buy" rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Finally, Chardan Capital raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $31.00.
Check Out Our Latest Report on STOK
Hedge Funds Weigh In On Stoke Therapeutics
A number of large investors have recently made changes to their positions in STOK. CANADA LIFE ASSURANCE Co lifted its holdings in Stoke Therapeutics by 12.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company's stock worth $296,000 after purchasing an additional 1,313 shares during the last quarter. Polar Capital Holdings Plc grew its holdings in Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock valued at $31,102,000 after buying an additional 439,824 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in Stoke Therapeutics during the 3rd quarter worth $5,875,000. Nomura Holdings Inc. acquired a new stake in shares of Stoke Therapeutics during the third quarter worth $1,908,000. Finally, Millennium Management LLC boosted its position in shares of Stoke Therapeutics by 199.3% in the third quarter. Millennium Management LLC now owns 61,048 shares of the company's stock valued at $1,435,000 after acquiring an additional 40,652 shares during the period.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
